Summary
Eli Lilly and Company (LLY) reported a robust third quarter of 2025, showcasing significant growth across key financial metrics. Revenue for the quarter surged by 54% year-over-year to $17.6 billion, driven by strong volume increases from Mounjaro and Zepbound, which experienced substantial growth both in the U.S. and internationally. This top-line performance translated into impressive profitability, with net income soaring by over 470% to $5.6 billion, and diluted earnings per share reaching $6.21, up from $1.07 in the prior year period. The company's gross margin improved to 82.9%, reflecting favorable product mix and cost efficiencies. Looking at the nine-month period, the positive trends continued, with revenue up 46% to $45.9 billion and net income more than doubling to $14.0 billion. These strong results highlight the company's successful execution in bringing novel therapies to market and expanding their reach. Lilly's ongoing investment in research and development remains substantial, underscoring its commitment to future innovation, while marketing and administrative expenses also increased to support commercial launches. The balance sheet remains strong, with a significant increase in cash and cash equivalents, providing flexibility for continued investment and strategic initiatives.
Financial Highlights
49 data points| Revenue | $17.60B |
| Cost of Revenue | $3.01B |
| Gross Profit | $14.59B |
| SG&A Expenses | $2.74B |
| Net Income | $5.58B |
| EPS (Basic) | $6.22 |
| EPS (Diluted) | $6.21 |
| Shares Outstanding (Basic) | 896.90M |
| Shares Outstanding (Diluted) | 898.80M |
Key Highlights
- 1Revenue for Q3 2025 reached $17.6 billion, a 54% increase year-over-year, driven by Mounjaro and Zepbound volume growth.
- 2Net income for Q3 2025 surged to $5.6 billion, a 473% increase from $0.97 billion in Q3 2024.
- 3Diluted EPS for Q3 2025 was $6.21, a significant increase from $1.07 in the prior year quarter.
- 4Gross margin improved to 82.9% in Q3 2025, up from 81.0% in Q3 2024, indicating enhanced profitability.
- 5Research and Development expenses increased by 27% year-over-year for the quarter, demonstrating continued investment in innovation.
- 6Marketing, selling, and administrative expenses rose by 31% for the quarter, supporting commercial efforts for key products.
- 7Cash and cash equivalents increased significantly to $9.79 billion as of September 30, 2025, up from $3.27 billion at the end of 2024.